Literature DB >> 21180573

Natalizumab: Increased Vigilance is Required in Treating Patients with Multiple Sclerosis.

Michael K Racke1, Olaf Stüve.   

Abstract

Entities:  

Year:  2008        PMID： 21180573      PMCID： PMC3002552          DOI： 10.1177/1756285608099125

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN： 1756-2856            Impact factor:   6.570


× No keyword cloud information.
  8 in total

1.  Immune surveillance in multiple sclerosis patients treated with natalizumab.

Authors:  Olaf Stüve; Christina M Marra; Keith R Jerome; Linda Cook; Petra D Cravens; Sabine Cepok; Elliot M Frohman; J Theodore Phillips; Gabriele Arendt; Bernhard Hemmer; Nancy L Monson; Michael K Racke
Journal:  Ann Neurol       Date:  2006-05       Impact factor: 10.422

2.  Melanoma complicating treatment with natalizumab for multiple sclerosis.

Authors:  John T Mullen; Timothy K Vartanian; Michael B Atkins
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245

3.  Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.

Authors:  Olaf Stüve; Christina M Marra; Amit Bar-Or; Masaaki Niino; Petra D Cravens; Sabine Cepok; Elliot M Frohman; J Theodore Phillips; Gabriele Arendt; Keith R Jerome; Linda Cook; Francois Grand'Maison; Bernhard Hemmer; Nancy L Monson; Michael K Racke
Journal:  Arch Neurol       Date:  2006-10

Review 4.  Central nervous system infections - a potential complication of systemic immunotherapy.

Authors:  Bernhard Hemmer; Eiliot Frohman; Hans Peter Hartung; Olaf Stüve
Journal:  Curr Opin Neurol       Date:  2006-06       Impact factor: 5.710

5.  Association of human herpesvirus 6 with the demyelinative lesions of progressive multifocal leukoencephalopathy.

Authors:  D J Mock; J M Powers; A D Goodman; S R Blumenthal; N Ergin; J V Baker; D H Mattson; J G Assouline; E J Bergey; B Chen; L G Epstein; B M Blumberg
Journal:  J Neurovirol       Date:  1999-08       Impact factor: 2.643

6.  Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.

Authors:  R Saccardi; A Tyndall; G Coghlan; C Denton; G Edan; M Emdin; D Farge; A Fassas; J Finke; D Furst; M Lassus; G Mancardi; I Miniati; E Mini; F Pagliai; J Passweg; A Pignone; J M van Laar; C Bocelli-Tyndall; M Matucci-Cerinic
Journal:  Bone Marrow Transplant       Date:  2004-11       Impact factor: 5.483

7.  Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis.

Authors:  Syed Khizer Hasan; Ashley N Mays; Tiziana Ottone; Antonio Ledda; Giorgio La Nasa; Chiara Cattaneo; Erika Borlenghi; Lorella Melillo; Enrico Montefusco; José Cervera; Christopher Stephen; Gnanam Satchi; Anne Lennard; Marta Libura; Jo Ann W Byl; Neil Osheroff; Sergio Amadori; Carolyn A Felix; Maria Teresa Voso; Wolfgang R Sperr; Jordi Esteve; Miguel A Sanz; David Grimwade; Francesco Lo-Coco
Journal:  Blood       Date:  2008-07-23       Impact factor: 22.113

8.  Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients.

Authors:  Karen Yao; Susan Gagnon; Nahid Akhyani; Elizabeth Williams; Julie Fotheringham; Elliot Frohman; Olaf Stuve; Nancy Monson; Michael K Racke; Steven Jacobson
Journal:  PLoS One       Date:  2008-04-30       Impact factor: 3.240
  8 in total
  1 in total

1.  Escalating immunotherapy of multiple sclerosis.

Authors:  Peter Rieckmann; Anthony Traboulsee; Virginia Devonshire; Joel Oger
Journal:  Ther Adv Neurol Disord       Date:  2008-11       Impact factor: 6.570
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.